Nottyboi,
There will likely be a treatment within the next two months. But FDA approval for a vaccine is estimated to be a much longer process.
Gilead Sciences (GILD - NASDAQ) has an anti-viral drug called Remdesivir that is being studied in five large clinical trials, two of which could read out results in early April. Up until now, Gilead has made it possible for patients who want the drug to get it through a process called “compassionate use.” To date, the company said, it has provided emergency access to several hundred patients in the United States, Europe, and Japan.
Remdesivir works by preventing the virus from replicating. It is delivered intraveneously. Watch for rush FDA approval sometime in April. Gilead is ramping up production all around the world and they will still be no where close to meeting demand.
Matt